ArticleBioinformation2024
Molecular docking and dynamics analysis of flavonoids from Retama monosperma with drug-resistant GIST mutations.
Article in Bioinformation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metadynamics reveals luteolin-mediated conformational stabilization against avapritinib-resistant PDGFRα D842V/G680R GIST.Scientific reports · 2026Article
- Integrated docking-molecular dynamics, ADME-toxicity profiling, and transcriptomic validation identify oroxylin a as a TLR7-targeting flavonoid candidate in systemic lupus erythematosus.Frontiers in chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal stromal tumors (GISTs), the most prevalent mesenchymal tumors of the gastrointestinal tract, are predominantly driven by activating mutations in receptor tyrosine kinases such as c-Kit and PDGFRα. Resistance to tyrosine kinase inhibitors (TKIs) poses a substantial therapeutic challenge, underscoring the need for novel treatments. Consequently, investigating the potential of natural compounds, specifically flavonoids from Retama monosperma, known for their diverse bioactivities, is of significant interest. Molecular docking and simulations revealed that Luteolin exhibited high binding affinities for PDGFRα (-8.1 kcal/mol) and c-KIT (-9.6 kcal/mol), comparable to Avapritinib and Sunitinib. The compound demonstrated favorable ADMET properties and formed notable hydrogen bonds and hydrophobic interactions with key residues in both targets. Molecular dynamic simulation over 100 ns revealed stable complexes with consistent RMSD and RMSF values. Additionally, Luteolin showed strong binding affinities to the resistant mutations c-Kit (D816H) and PDGFRα (T674I), with enhanced stability. These findings suggest that Luteolin has significant potential as a dual inhibitor and offers a promising alternative to conventional TKIs for addressing GIST resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.